Literature DB >> 16800840

The impact of genotype on endocrine complications in thalassaemia major.

Nicos Skordis1, Monica Michaelidou, Savvas C Savva, Yiannis Ioannou, Andreas Rousounides, Marina Kleanthous, George Skordos, Soteroulla Christou.   

Abstract

BACKGROUND: The clinical severity in thalassaemia major (TM) depends on the underlying mutations of the beta-globin gene and the degree of iron overload.
OBJECTIVE: The aim of the study was to investigate the impact of genotype on the development of endocrine complications in TM in our center. SUBJECTS AND METHODS: 126 (62 males, 64 females) thalassaemic patients of Greek Cypriot origin with a mean age of 31.2 (17-68) yr were included in the study. All patients, who were on the standard treatment protocol, were subsequently divided into two groups according to their genotype, group A (92): TM with no mitigating factor and group B (34): TM carrying one or more mitigating factors in the beta- and/or alpha-globin genes. Iron overload calculation was based on the amount of red cell consumption and the mean ferritin level over a 12-year period. Statistical analysis was performed with the SPSS program.
RESULTS: Patients in group A, who were consuming larger amounts of blood on transfusions, were more likely to develop hypogonadism (P = 0.001) compared with patients in group B, despite their similar mean ferritin levels. The incidence of other endocrinopathies (short stature, hypothyroidism, and diabetes mellitus) was similar in the two groups. The prevalence of hypothyroidism in splenectomized patients was significantly higher (P = 0.005), whereas the presence of hypogonadism, impaired glucose homeostasis and insulin resistance, although more frequent, was not statistically significant. The clinical severity of TM had no impact on bone mineral density (BMD) in both men and women. BMD was only influenced by gonadal function.
CONCLUSIONS: This study demonstrates that the underlying genetic defect in TM is a contributing factor for gonadal dysfunction, because the patients with the more severe defects have a greater rate of iron loading through higher red cell consumption.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16800840     DOI: 10.1111/j.1600-0609.2006.00681.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  18 in total

Review 1.  Growth and endocrine function in thalassemia major in childhood and adolescence.

Authors:  M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2010-01       Impact factor: 4.256

2.  Impact of Genotype of Beta Globin Gene on Hepatic and Myocardial Iron Content in Egyptian Patients with Beta Thalassemia.

Authors:  Tamer H Hassan; Mohamed M Abdel Salam; Marwa Zakaria; Mohamed Shehab; Dina T Sarhan; El Sayed H Zidan; Khaled M El Gerby
Journal:  Indian J Hematol Blood Transfus       Date:  2018-11-08       Impact factor: 0.900

3.  Thyroid dysfunction in Greece: Results from the national health examination survey EMENO.

Authors:  Paraskevi V Voulgari; Aliki I Venetsanopoulou; Natasa Kalpourtzi; Magda Gavana; Apostolos Vantarakis; Christos Hadjichristodoulou; Grigoris Chlouverakis; Grigoris Trypsianis; Yannis Alamanos; Giota Touloumi
Journal:  PLoS One       Date:  2022-03-04       Impact factor: 3.240

4.  Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America.

Authors:  Maria G Vogiatzi; Eric A Macklin; Felicia L Trachtenberg; Ellen B Fung; Angela M Cheung; Elliott Vichinsky; Nancy Olivieri; Melody Kirby; Janet L Kwiatkowski; Melody Cunningham; Ingrid A Holm; Martin Fleisher; Robert W Grady; Charles M Peterson; Patricia J Giardina
Journal:  Br J Haematol       Date:  2009-07-13       Impact factor: 6.998

5.  Osteoporosis syndrome in thalassaemia major: an overview.

Authors:  Meropi Toumba; Nicos Skordis
Journal:  J Osteoporos       Date:  2010-05-26

6.  Impact of genotype on endocrinal complications in β-thalassemia patients.

Authors:  Ahmed Al-Akhras; Mohamed Badr; Usama El-Safy; Elisabeth Kohne; Tamer Hassan; Hadeel Abdelrahman; Mohamed Mourad; Joaquin Brintrup; Marwa Zakaria
Journal:  Biomed Rep       Date:  2016-04-04

7.  Evaluation of the glucocorticoid, mineralocorticoid, and adrenal androgen secretion dynamics in a large cohort of patients aged 6-18 years with transfusion-dependent β-thalassemia major, with an emphasis on the impact of cardiac iron load.

Authors:  Ahmet Uçar; Nergiz Öner; Gülcihan Özek; Mehmet Güli Çetinçakmak; Mahmut Abuhandan; Ali Yıldırım; Cemil Kaya; Sena Ünverdi; Hamdi Cihan Emeksiz; Yasin Yılmaz; Aylin Yetim
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

8.  Thalassaemia and aberrations of growth and puberty.

Authors:  Andreas Kyriakou; Nicos Skordis
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-07-27       Impact factor: 2.576

9.  Longitudinal study on thyroid function in patients with thalassemia major: High incidence of central hypothyroidism by 18 years.

Authors:  Ashraf T Soliman; Fawzia Al Yafei; Lolwa Al-Naimi; Noora Almarri; Aml Sabt; Mohamed Yassin; Vincenzo De Sanctis
Journal:  Indian J Endocrinol Metab       Date:  2013-11

10.  Bone density in transfusion dependent thalassemia patients in Urmia, Iran.

Authors:  N Valizadeh; F Farrokhi; V Alinejad; Sm Said Mardani; N Valizadeh; S Hejazi; M Noroozi
Journal:  Iran J Ped Hematol Oncol       Date:  2014-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.